Document is current

Article History

Received: 27 September 2023

Accepted: 6 June 2024

First Online: 3 July 2024

Declarations

:

: Craig Versek and Srinivas Sridhar declare financial compensation from and financial interest in NeuroFieldz Inc, which is commercializing the NeuroVEP testing system.

: This study was approved by the Northeastern University and Tufts Medical Center Institutional Review Boards (IRB Study # 13395, Protocol title: Objective Portable Diagnostics of Neurological Disorders using Visual Evoked Potentials) and was performed in accordance with the Declaration of Helsinki. All subjects were either referred by their clinical neurologist at the Department of Neurology at Tufts Medical Center or were self-enrolled after seeing an advertisement posted around Tufts Medical Center.

: no animals were used in this research

: Subjects were required to be between 18 and 80 years of age and signed a written informed consent document after the study was explained and all of their questions were answered. Gender was not used as a condition for selection. 10 healthy subjects along with 10 subjects with MS, ON or both conditions were tested. Because of the virtual reality (VR) capabilities of our display system, we required subjects to fill out a simulator sickness questionnaire; however, the static nature of our stimuli was not expected to induce motion sickness symptoms, and this was borne out in the results (no discomfort was reported in the subject feedback). Three of the authors served as control subjects (SMAB, CV, and SS), who have extensive experience participating in EEG and/or psychophysical vision testing paradigms.